Cargando…
Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are present in 20–40% of non-small cell lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC (25–45%) compared to EGFR wild-type (15–30%). First and second-generation tyrosine kinase inhibitors (TKIs), such as erlotinib a...
Autores principales: | Bhandari, Shruti, Dunlap, Neal, Kloecker, Goetz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182502/ https://www.ncbi.nlm.nih.gov/pubmed/34164215 http://dx.doi.org/10.21037/jtd-2019-rbmlc-04 |
Ejemplares similares
-
Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer
por: Suwinski, Rafal
Publicado: (2021) -
Radiotherapy for brain metastases from small-cell lung cancer in distinct clinical indications and scenarios
por: Kepka, Lucyna, et al.
Publicado: (2021) -
Treatment of brain metastases from lung cancer: challenging the historical nihilism concerning prognosis
por: Kepka, Lucyna
Publicado: (2021) -
WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view
por: Sas-Korczynska, Beata, et al.
Publicado: (2021) -
Management of brain metastases in elderly patients with lung cancer
por: Socha, Joanna, et al.
Publicado: (2021)